Company
SinoMab Bioscience Limited (SinoMab) is a private company established in 2001 by a team of antibody and biotechnology professionals. It is a clinical stage biopharmaceutical company that creates and develops therapeutic antibodies.
SinoMab has obtained three Investigational New Drug (IND) approval from China FDA for developing one of its lead products for non-Hodgkin’s Lymphoma (NHL) (淋巴癌), systemic lupus erythematosus (SLE) (紅斑狼瘡) and rheumatoid arthritis (RA) (類風濕關節炎).
Therapeutic Monoclonal antibodies including and Sm03 and SM09, and other Biosimilars.
Description
SinoMab Bioscience Limited (SinoMab) is a private company established in 2001 by a team of antibody and biotechnology professionals. It is a clinical stage biopharmaceutical company that creates and develops therapeutic antibodies. SinoMab has obtained three Investigational New Drug (IND) approval from China FDA for developing one of its lead products for non-Hodgkin’s Lymphoma (NHL) (淋巴癌), systemic lupus erythematosus (SLE) (紅斑狼瘡) and rheumatoid arthritis (RA) (類風濕關節炎).
